openPR Logo
Press release

Urothelial Carcinoma Treatment Market : Trends and Key Developments 2016 - 2024

07-31-2017 09:53 PM CET | Health & Medicine

Press release from: Transparency Market Research

Urothelial Carcinoma Treatment Market : Trends and Key

Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma is also known as transitional cell carcinoma. Bladder transitional cell carcinoma (TCC) is the most common tumor of the entire urinary system and TCC is the most common primary neoplasm of the urinary bladder. Cancer of the ureter may not have symptoms in the early stages of the disease. However, symptoms may appear as the cancer grows. These include: persistent back pain, blood in the urine, painful or frequent urination, fatigue unexplained weight loss. These symptoms are associated with malignant cancer of the ureter and other health conditions. 

View Report @ http://www.transparencymarketresearch.com/urothelial-carcinoma-treatment-market.html

The treatment of Urothelial carcinoma involves surgery, chemotherapy and radiotherapy. The tests to diagnose Urothelial carcinoma includes Urine tests, Ureteroscopy, Intravenous pyelogram (IVP), Retrograde pyelography, CT scan, MRI scan and Chest X-ray. While the treatment with surgery include open surgery, laparoscopic surgery and percutaneous endoscopic surgery. Chemotherapy treatment usually involves the treatment with a combination of drugs. The combinations includes: gemcitabine and cisplatin, gemcitabine and carboplatin as well as methotrexate, vinblastine, doxorubicin and cisplatin. Radiotherapy is not frequently used for transitional cell carcinoma of the kidney or ureter. Patient may have radiotherapy to the area of the ureter or kidney if patients are not fit enough to have an operation or cancer has spread into surrounding tissue.

The Urothelial carcinoma market has been segmented by type of drugs, by end-user and by geography. The type of drugs sub-segmented as targeted and chemotherapy. The drugs like Levatinib, Atezolizumab, Nivelumab, Enzalutamide, Abiraterone acetate, Cabazitaxel, sipuleucel-T, everolimus, bevacizumab and pazopanib are used in treatment of Urothelial carcinoma. The end-users for the Urothelial carcinoma market include Hospitals, Specialty Clinics, Cancer Research Institutes and Ambulatory Surgical Centers.

Belgium holds the top rank in incidences of bladder cancer, which is followed by Lebanon and Malta. Bladder cancer cases occur in more developed countries, notably around 59%. The regions like Northern America and Europe having highest incidence of bladder cancer; and Asia, Latin America and the Caribbean having the lowest incidence. Transitional cell cancer develops in the part of the kidney called the renal pelvis. Transitional cell cancers are rare and only about 7 out of 100 kidney cancers (7%) diagnosed in the UK. The most common type of kidney cancer is renal cell cancer. Transitional cell cancer of the ureter is even more infrequent than transitional cell cancer of the kidney. TCC of the kidney is 4 times more common than cancer of the ureter. The most common type of bladder cancer is transitional cell cancers of the bladder. According to the estimation of American Cancer Society for bladder cancer, in 2016 there would be about 76,960 new cases of bladder cancer, and about 16,390 deaths from bladder cancer alone in the United States. In recent years the rates of cancer deaths and new bladder cancers have been dropping slightly in women. Incidence rates have been decreasing and death rates have been stable in men. About 5% of all newly diagnosed cancers in the US are Bladder cancers. It is the fourth most frequent cancer in men, but it is not common in women.

Get accurate market forecast and analysis on the Urothelial Carcinoma Treatment Market. Request a sample to stay abreast on the key trends impacting this market.

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14060

The major players operating in Urothelial carcinoma market include Genentech, GlaxoSmithKline, Genentech, Novartis, Dendreon, Sanofi Aventis, Bristol-Myers Squibb and Eisai are among other significant players worldwide.

The report offers a comprehensive evaluation of the market. It does so via in-depth insights, understanding market evolution by tracking historical developments, and analyzing the present scenario and future projections based on optimistic and likely scenarios. Each research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology developments, types, applications, and the competitive landscape. 

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Urothelial Carcinoma Treatment Market : Trends and Key Developments 2016 - 2024 here

News-ID: 649138 • Views: 273

More Releases from Transparency Market Research

Potassium Bicarbonate Market Technological breakthroughs, Value chain and stakeh …
Overview TMR’s report on the Potassium Bicarbonate Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Potassium Bicarbonate serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Potassium Bicarbonate over the forecast period. These indicators help businesses
Liquid Analytical Instruments Market Global Market Opportunity Assessment Study …
Overview TMR’s report on the Liquid Analytical Instruments Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Liquid Analytical Instruments serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Liquid Analytical Instruments over the forecast period. These
Boron Oxide Market Growth Prospects, Trends and Forecast up to 2023
Overview TMR’s report on the Boron Oxide Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Boron Oxide serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Boron Oxide over the forecast period. These indicators help businesses
Hydrochloric Acid Market to Witness a Pronounce Growth During 2016 - 2024
Overview TMR’s report on the Hydrochloric Acid Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services. Our research report on the Hydrochloric Acid serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Hydrochloric Acid over the forecast period. These indicators help businesses

All 5 Releases


More Releases for Urothelial

Urothelial Cancer Drugs - Product Modifications 2028 | Market AstraZeneca, Merck
Global Urothelial Cancer Drugs Market: Overview Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder which can spread to other parts of the body. The urothelium comprises of the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. All those comprise of the urothelial cells, or transitional cells. Urothelial carcinoma is the most widespread bladder cancer. It
Urothelial Cancer Drugs Market - Players largest contributor 2028 | Roche, Astra …
Global Urothelial Cancer Drugs Market: Overview Urothelial carcinoma, also known as transitional cell carcinoma, is a cancerous tumor of the bladder which can spread to other parts of the body. The urothelium comprises of the lining on the inside of the bladder, urethra, and ureters. It also consists of the renal pelvis. All those comprise of the urothelial cells, or transitional cells. Urothelial carcinoma is the most widespread bladder cancer. It
Urothelial Carcinoma Treatment Market to Record Study Growth by 2024
Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma
Urothelial Carcinoma Diagnostics Market Forecast over 2017 – 2025
Urothelial Carcinoma or Transitional Cell Carcinoma encompasses cancer in different parts of urinary tract like kidney, bladder, ureters, and renal pelvis. Bladder tumors account for 90-95% of urothelial carcinoma. Urothelial Carcinoma occur more commonly in men than in women with the ratio of 3:1. Tobacco smoking, Coffee drinking, analgesic abuse, some occupational exposures are the factors that promote urothelial carcinoma. The urothelial carcinoma diagnosis involves the tests that are used
Urothelial Carcinoma Treatment Market : Evolving Market Trends & Dynamics 2024
Urothelial carcinoma is a malignant neoplasm resulting from transitional epithelium, occurring mainly in the urinary bladder, renal pelves or ureters; frequently papillary. These carcinomas are classified according to the degree of anaplasia. Urothelial cell carcinoma (UCC) is a type of cancer that normally occurs in the urinary system: urinary bladder, kidney and accessory organs. It is the most common type of bladder, ureter, urethra, and urachus cancer. Urothelial cell carcinoma
Urothelial Carcinoma Diagnostics Market Size, Status and Forecast 2017 – 2025
Urothelial Carcinoma or Transitional Cell Carcinoma encompasses cancer in different parts of urinary tract like kidney, bladder, ureters, and renal pelvis. Bladder tumors account for 90-95% of urothelial carcinoma. Urothelial Carcinoma occur more commonly in men than in women with the ratio of 3:1. Tobacco smoking, Coffee drinking, analgesic abuse, some occupational exposures are the factors that promote urothelial carcinoma. The urothelial carcinoma diagnosis involves the tests that are used